Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to...
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Suboptimal treatment upon progression may affect overall survival (OS) results in oncology randomized controlled trials (RCTs). We aim to assess the proportion of trials reporting post-progression treatment.
This cross-sectional analysis included two concurrent analyses. The first one examined all published RCTs of anti-cancer drugs in six high...
Alternative Titles
Full title
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d1f1877d23384ac68ac5b418fe6d8208
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d1f1877d23384ac68ac5b418fe6d8208
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-023-10917-z
